Wolfgang Hiddemann

1949 -

country of citizenship: Germany

languages spoken, written or signed: German

occupation: university teacher, physician, internist

Wolfgang Hiddemann (* 18. Mai 1949 in Köln) ist ein deutscher Hämatologe und Onkologe und Professor an der Ludwig-Maximilians-Universität München. Source: Wikipedia (de)

Series

There is nothing here

Create a new serie

Works

There is nothing here

Create a new work

Articles 57

Date

Title

Authors

2020-01-02

The clinical mutatome of core binding factor leukemia

Klaus H Metzeler, Tobias Herold, Stefan K. Bohlander, Philipp A Greif, Christian Thiede, Gerhard Ehninger, Johannes Schetelig, Maria-Cristina Sauerland, Alwin Krämer, Jan Moritz Middeke, Christoph Röllig, Wolfgang Hiddemann, Bianka Ksienzyk, Sebastian Vosberg, Helmut Blum, Karsten Spiekermann
2018-06-15

Development and Evaluation of an Ethical Guideline for Decisions to Limit Life-Prolonging Treatment in Advanced Cancer: Protocol for a Monocentric Mixed-Method Interventional Study

Katsiaryna Laryionava, Katja Mehlis, Elena Bierwirth, Friederike Mumm, Wolfgang Hiddemann, Pia Heußner, Eva C Winkler
2017-03-09

Targeting CD157 in AML using a novel, Fc-engineered antibody construct

Wolfgang Hiddemann
2017-11-09

FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy

Pedro Farinha, Anja Mottok, Ellen Leich, German Ott, Christian Steidl, Joseph M Connors, Randy D Gascoyne, Eva Hoster, Oliver Weigert, Robert Kridel, Andreas Rosenwald, Laurie H Sehn, Vindi Jurinovic, Wolfram Klapper, Wolfgang Hiddemann
2017-08-15

Validation of a Molecular Risk Score for Prognosis of Patients With Acute Promyelocytic Leukemia Treated With All-trans Retinoic Acid and Chemotherapy-containing Regimens.

Gerhard Ehninger, Uwe Platzbecker, Christoph Röllig, Wolf-Karsten Hofmann, Florian Nolte, Wolfgang Hiddemann, Karsten Spiekermann, Heidi Altmann
2016-06-10

Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia

Klaus H Metzeler, Tobias Herold, Susanne Amler, Dennis Görlich, Philipp A Greif, Karsten Spiekermann, Wolfgang Hiddemann, Annika Dufour, Evelyn Zellmeier
2016-07-14

Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy

Monika Szczepanowski, Joseph M Connors, Randy D Gascoyne, Andreas Rosenwald, Andrew D Zelenetz, Laurie H Sehn, Jonathan W Friedberg, Vindi Jurinovic, Robert Kridel, Annette M Staiger, Wolfram Klapper, Oliver Weigert, Wolfgang Hiddemann
2015

An advanced preclinical mouse model for acute myeloid leukemia using patients' cells of various genetic subgroups and in vivo bioluminescence imaging

Binje Vick, Andreas Trumpp, Martin Ebinger, Klaus H Metzeler, Irmela Jeremias, Wolfgang Hiddemann, Nadine Sandhöfer
2015-09

Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry

Martin Dreyling, German Ott, Andreas Rosenwald, Monika Szczepanowski, Eva Hoster, Joseph M Connors, Randy D Gascoyne, Wolfgang Hiddemann, Christiane Pott, Donna Neuberg, Laurie H Sehn, Anja Mottok, Ellen Leich, Vindi Jurinovic, Robert Kridel, Annette M Staiger, Alden A Moccia, Daisuke Ennishi, Hennady P Shulha, Christoffer Hother, Wolfram Klapper, Oliver Weigert
2015-05-21

Identification of the Adapter Molecule MTSS1 as a Potential Oncogene-Specific Tumor Suppressor in Acute Myeloid Leukemia

Steffen Koschmieder, Carsten Müller-Tidow, Steffen Koschmieder, Wolfgang Hiddemann
2014-05-09

Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse

Eva Hoster, Stefan K. Bohlander, Wolfgang Hiddemann, Annika Dufour, Evelyn Zellmeier
2014-09-10

Long-term follow-up of cytogenetically normal CEBPA-mutated AML

Eva Hoster, Wolfgang Hiddemann, Friederike Pastore, Annika Dufour, Bernhard J Woermann
2014-10-09

The NPM1 mutation type has no impact on survival in cytogenetically normal AML

Philipp A Greif, Wolfgang Hiddemann, Friederike Pastore, Evelyn Zellmeier, Bernhard J Woermann
2014-10-30

Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial

Nicola Gökbuget, Andreas Hüttmann, Thomas Burmeister, Hubert Serve, Rainer Fietkau, Hartmut Döhner, Jan Walewski, Wolfgang Hiddemann, Michael Kneba
2014-10-31

What keeps oncologists from addressing palliative care early on with incurable cancer patients? An active stance seems key

Katsiaryna Laryionava, Wolfgang Hiddemann
2014-12-01

Preclinical efficacy of maternal embryonic leucine-zipper kinase (MELK) inhibition in acute myeloid leukemia

Houda Alachkar, Klaus H Metzeler, Tobias Herold, Wolfgang Hiddemann
2014-03-07

Activating FLT3 mutants show distinct gain-of-function phenotypes in vitro and a characteristic signaling pathway profile associated with prognosis in acute myeloid leukemia

Karl-Peter Hopfner, Tobias Herold, Stefan K. Bohlander, Wolfgang Hiddemann, Friederike Pastore, Bernhard J Woermann
2014-04-14

The role of therapeutic leukapheresis in hyperleukocytotic AML.

Wolfgang Hiddemann, Friederike Pastore
2014-04-07

Combined molecular and clinical prognostic index for relapse and survival in cytogenetically normal acute myeloid leukemia

Eva Hoster, Stefan K. Bohlander, Klaus H Metzeler, Guido Marcucci, Clara D. Bloomfield
2014-06-12

Isolated trisomy 13 defines a homogeneous AML subgroup with high frequency of mutations in spliceosome genes and poor prognosis

Tobias Herold, Klaus H Metzeler, Stefan K. Bohlander, Gerhard Ehninger, Martin Bornhäuser, Christoph Röllig, Maria-Cristina Sauerland, Philipp A Greif, Wolfgang Hiddemann, Bianka Ksienzyk, Sebastian Vosberg, Helmut Blum, Karsten Spiekermann, Thomas Buchner
2013-02-04

Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative study

Guido Marcucci, Konstanze Döhner, Clara D. Bloomfield, Bob Löwenberg, Michael A Caligiuri, Chunjiang He, Janet Rowley, Michelle M Le Beau, Richard A. Larson, Tobias Herold, Stefan K. Bohlander, Mary Beth Neilly, Paul Liu, Peter J M Valk, Xinan Yang, Lars Bullinger
2013-10-04

Intensive induction is effective in selected octogenarian acute myeloid leukemia patients: prognostic significance of karyotype and selected molecular markers used in the European LeukemiaNet classification

Richard A. Larson, Guido Marcucci, Hartmut Döhner, Clara D. Bloomfield, Krzysztof Mrózek, Hervé Dombret, Jessica Kohlschmidt, Meir Wetzler, Thomas Buchner
2012-09-04

CD86 and IL-12p70 are key players for T helper 1 polarization and natural killer cell activation by Toll-like receptor-induced dendritic cells

Wolfgang Hiddemann
2012-09-07

Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial.

Gerhard Ehninger, Martin Bornhäuser, Johannes Schetelig, Dietrich W Beelen, Matthias Stelljes, Kerstin Schäfer-Eckart, Michael Kiehl, Andreas Burchert, Rainer Schwerdtfeger, Rudolf Trenschel, Ute Hegenbart, Joachim Kienast, Herrad Baurmann, Stefanie Buchholz, Wolfgang Hiddemann, Peter Dreger
2011-04-01

Allogeneic transplantation as post-remission therapy for cytogenetically high-risk acute myeloid leukemia: landmark analysis from a single prospective multicenter trial

Carsten Müller-Tidow, Wolfgang Hiddemann
2010-09-10

The vent-like homeobox gene VENTX promotes human myeloid differentiation and is highly expressed in acute myeloid leukemia

Farid Ahmed, Medhanie A Mulaw, Silvia Thoene, Stefan K. Bohlander, Wolfgang Hiddemann, Michaela Feuring-Buske
2010-12-03

Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes

Hubert Serve, Steffen Koschmieder, Carsten Müller-Tidow, Torsten Haferlach, Claudia Haferlach, Gerhard Ehninger, Christian Thiede, Thomas Buchner, Jan Braess, Karsten Spiekermann, Maria-Cristina Sauerland, Achim Heinecke, Bernhard Wörmann, Utz Krug, Christoph Röllig, Markus Schaich, Study Alliance Leukemia Investigators, Wolfgang Hiddemann, Anja Koschmieder
2009-01-01

Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group

Carsten Müller-Tidow, Torsten Haferlach, Claudia Haferlach, Susanne Schnittger, Carlo Aul, Thomas Buchner, Jan Braess, Karsten Spiekermann, Eva Lengfelder, Maria-Cristina Sauerland, Achim Heinecke, Bernhard Wörmann, Wolfgang Hiddemann
2009-03-01

2-D PAGE-based comparison of proteasome inhibitor bortezomib in sensitive and resistant mantle cell lymphoma

Andreas Rosenwald, Wolfgang Hiddemann
2009-12-23

Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study

Olivier Hermine, Evelyne Callet-Bauchu, Eva Hoster, Jan Walewski, Marek Trněný, Hanneke C Kluin-Nelemans, Reiner Siebert, Wolfgang Hiddemann, Christiane Pott, Michael Kneba, Jacques J M van Dongen
2008-08-20

An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia

Klaus H Metzeler, Stefan K. Bohlander, Richard A. Larson, Cancer and Leukemia Group B, Guido Marcucci, Clara D. Bloomfield, Kati Maharry, Wolfgang Hiddemann
2007-10-25

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

Eva Hoster, Hanneke C Kluin-Nelemans, Hermann Einsele, Michael Pfreundschuh, Wolfgang Hiddemann, Hannes Wandt

Human - wd:Q23062357

Welcome to Inventaire

the library of your friends and communities

learn more